CA2616845A1 - Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees - Google Patents
Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees Download PDFInfo
- Publication number
- CA2616845A1 CA2616845A1 CA002616845A CA2616845A CA2616845A1 CA 2616845 A1 CA2616845 A1 CA 2616845A1 CA 002616845 A CA002616845 A CA 002616845A CA 2616845 A CA2616845 A CA 2616845A CA 2616845 A1 CA2616845 A1 CA 2616845A1
- Authority
- CA
- Canada
- Prior art keywords
- hardness
- eudragit
- amount
- tablet
- dependent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70300005P | 2005-07-28 | 2005-07-28 | |
US60/703,000 | 2005-07-28 | ||
PCT/US2006/029427 WO2007016350A2 (fr) | 2005-07-28 | 2006-07-28 | Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2616845A1 true CA2616845A1 (fr) | 2007-02-08 |
Family
ID=37692541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002616845A Abandoned CA2616845A1 (fr) | 2005-07-28 | 2006-07-28 | Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1909767A2 (fr) |
JP (1) | JP2009502957A (fr) |
CA (1) | CA2616845A1 (fr) |
WO (1) | WO2007016350A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009087663A2 (fr) * | 2007-11-30 | 2009-07-16 | Sun Pharmaceutical Industries Ltd. | Comprimé oral enrobé à libération contrôlée |
CN102216458B (zh) | 2008-11-13 | 2017-05-24 | 诺格拉制药有限公司 | 反义组合物及其制备和使用方法 |
AT10562U3 (de) * | 2008-12-05 | 2010-01-15 | Aop Orphan Pharmaceuticals Ag | Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie |
LT2531181T (lt) * | 2010-02-03 | 2019-07-10 | Pharma Two B Ltd. | Rasagilino uždelsto atpalaidavimo kompozicijos ir jų panaudojimas |
CN102138906B (zh) * | 2011-04-11 | 2012-09-05 | 合肥合源药业有限公司 | 一种盐酸可乐定缓释微丸制剂 |
EP4292587A1 (fr) | 2022-06-15 | 2023-12-20 | Sawai Pharmaceutical Co., Ltd. | Préparation pharmaceutique contenant du chlorhydrate de guanfacine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2781152B1 (fr) * | 1998-07-20 | 2001-07-06 | Permatec Tech Ag | Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation |
US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
US6811794B2 (en) * | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
-
2006
- 2006-07-28 EP EP06788799A patent/EP1909767A2/fr not_active Withdrawn
- 2006-07-28 JP JP2008524198A patent/JP2009502957A/ja active Pending
- 2006-07-28 WO PCT/US2006/029427 patent/WO2007016350A2/fr active Application Filing
- 2006-07-28 CA CA002616845A patent/CA2616845A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1909767A2 (fr) | 2008-04-16 |
JP2009502957A (ja) | 2009-01-29 |
WO2007016350A2 (fr) | 2007-02-08 |
WO2007016350A3 (fr) | 2007-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002249881B2 (en) | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles | |
US6811794B2 (en) | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles | |
AU2002249881A1 (en) | Sustained release pharmaceutical dosage forms with minimized PH dependent dissolution profiles | |
US6893661B1 (en) | Controlled release formulations using intelligent polymers | |
EP2397122B1 (fr) | Formulations de formes pharmaceutiques de néramexane | |
JP5726401B2 (ja) | 単回投与形態の連日投与に適したグアンファシンの医薬品の剤形/組成物 | |
US20060193912A1 (en) | Controlled release O-desmethylvenlafaxine formulations | |
JPWO2006070781A1 (ja) | 塩基性薬物又はその塩を含有するマトリックス型徐放性製剤およびその製造方法 | |
RU2414241C2 (ru) | Лекарственные композиции, содержащие гипромеллозные матрицы контролируемого высвобождения | |
CA2616845A1 (fr) | Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees | |
US9616027B2 (en) | Pramipexole sustained release tablet formulation and manufacturing method thereof and use thereof | |
WO2014151797A1 (fr) | Formulations à libération prolongée résistant à la décharge de la dose d'alcool | |
JPWO2007080776A1 (ja) | 徐放性製剤およびその製造方法 | |
US20070104782A1 (en) | Modified release tablet formulations with enhanced mechanical properties | |
WO2004037228A1 (fr) | Compositions a liberation prolongee contenant de l'alfuzosine | |
EP2801350B1 (fr) | Formulations pharmaceutiques de lacosamide | |
US7632521B2 (en) | Controlled release potassium chloride tablets | |
CA3069948A1 (fr) | Composition a dose fixe buccale solide comprenant de la metformine, du valsartan et de l'atorvastatine | |
TW201609196A (zh) | 控制釋放製劑及其製備方法 | |
EP3843702A1 (fr) | Combinaison à dose fixe et à libération immédiate de mémantine et de donépézil | |
NZ760868B2 (en) | A solid oral fixed dose composition comprising metformin, valsartan and atorvastatin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |